首页> 美国卫生研究院文献>other >Filtration Device for On-Site Collection Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer
【2h】

Filtration Device for On-Site Collection Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer

机译:尿中细胞的现场收集贮存和运输的过滤装置及其在基于DNA的膀胱癌检测中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Molecular analysis of cells from urine provides a convenient approach to non-invasive detection of bladder cancer. The practical use of urinary cell-based tests is often hampered by difficulties in handling and analyzing large sample volumes, the need for rapid sample processing to avoid degradation of cellular content, and low sensitivity due to a high background of normal cells. We present a filtration device, designed for home or point-of-care use, which enables collection, storage and shipment of urinary cells. A special feature of this device is a removable cartridge housing a membrane filter, which after filtration of urine can be transferred to a storage unit containing an appropriate preserving solution. In spiking experiments, the use of this device provided efficient recovery of bladder cancer cells with elimination of >99% of excess smaller-sized cells. The performance of the device was further evaluated by DNA-based analysis of urinary cells collected from 57 patients subjected to transurethral resection following flexible cystoscopy indicating the presence of a tumor. All samples were tested for FGFR3 mutations and seven DNA methylation markers (BCL2, CCNA1, EOMES, HOXA9, POU4F2, SALL3 and VIM). In the group of patients where a transitional cell tumor was confirmed at histopathological evaluation, urine DNA was positive for one or more markers in 29 out of 31 cases (94%), including 19 with FGFR3 mutation (61%). In the group of patients with benign histopathology, urine DNA was positive for methylation markers in 13 out of 26 cases (50%). Only one patient in this group was positive for a FGFR3 mutation. This patient had a stage Ta tumor resected 6 months later. The ability to easily collect, store and ship diagnostic cells from urine using the presented device may facilitate non-invasive testing for bladder cancer.
机译:尿液细胞的分子分析为膀胱癌的非侵入性检测提供了一种方便的方法。在处理和分析大量样品时遇到困难,对快速样品处理以避免细胞含量降低的需求以及由于正常细胞的高背景而导致的灵敏度低通常会妨碍基于尿细胞测试的实际使用。我们提供了一种专为家庭或护理现场使用而设计的过滤设备,可实现尿细胞的收集,存储和运输。该设备的一个特殊功能是装有膜过滤器的可移动滤筒,在过滤尿液之后,该滤筒可以转移到包含适当保存溶液的存储单元中。在加标实验中,使用该设备可有效回收膀胱癌细胞,并消除了超过99%的过量小细胞。对该设备的性能进行了进一步的评估,方法是对来自57例行软性膀胱镜检查后行经尿道切除术的患者收集的尿细胞进行基于DNA的分析,从而表明存在肿瘤。测试所有样品的FGFR3突变和七个DNA甲基化标记(BCL2,CCNA1,EOMES,HOXA9,POU4F2,SALL3和VIM)。在经组织病理学检查证实为移行细胞瘤的患者中,尿液DNA在31例患者中有29例(94%)中的一种或多种标志物呈阳性,其中19例具有FGFR3突变(61%)。在良性组织病理学患者组中,26例患者中有13例尿液DNA甲基化标记阳性(50%)。该组中只有一名患者的FGFR3突变为阳性。该患者在六个月后切除了Ta期肿瘤。使用本发明的装置容易从尿液收集,存储和运送诊断细胞的能力可以促进膀胱癌的非侵入性测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号